Skip to main content
TipRanks
Go Ultimate75% OFF

Livzon Pharmaceutical Group (1513) Stock Price & Analysis

1 Followers

1513 Stock Chart & Stats

HK$24.98-HK$0.02(-0.08%)
At close: 4:00 PM GMT+8
HK$20HK$22.5HK$25Aug 24Sep 7Sep 21Oct 5Oct 20Nov 2Nov 16
Day’s Range
HKD 24.74 - HKD 25.28
52-Week Range
HKD 19.80 - HKD 32.94
Previous Close
HKD 25.00
Volume
N/A
Average Volume (3M)
1.38M
Market Cap
HKD 29.40B
Enterprise Value
HKD 17.84B
Total Cash (Recent Filing)
HKD 7.31B
Total Debt (Recent Filing)
HKD 4.20B
Price to Earnings (P/E)
18.1
Beta
0.70
Next Earnings
Mar 31, 2027 (Est.)
Dividend Yield
6.22%

Bulls Say, Bears Say

Bulls Say

Strong Profitability

Sustained gross and net margins at these levels indicate a profitable pharmaceutical portfolio with meaningful earnings retained from sales. This margin base can support research investment, commercialization and resilience over the next several quarters, provided current products remain competitive.

Positive Free Cash Flow

Strong free cash flow relative to net income shows that Livzon is converting accounting profits into internally generated funds. That provides flexibility to support product development, capital allocation and shareholder returns without relying as heavily on external financing.

Moderate Leverage

Moderate leverage and a substantial equity base provide financial stability for a pharmaceutical business operating through product and earnings cycles. The balance sheet should retain capacity to fund operations and strategic investment while limiting pressure from debt obligations.

Bears Say

Revenue Contraction

The recent revenue decline follows a period of limited growth, indicating that the company is not currently expanding its top line consistently. If this persists, weaker scale benefits could constrain future earnings growth and reduce the resources available for portfolio investment.

Earnings And Return Erosion

Falling EPS and lower returns on equity show that recent profitability has weakened relative to the capital employed. Continued deterioration would reduce the company’s ability to compound shareholder value and could signal less efficient deployment of investment across its business.

Uneven Cash Conversion

Although free cash flow remains positive, its recent decline and only moderate operating cash flow coverage indicate that cash conversion is not consistently best-in-class. Such variability can make funding for development, investment and distributions less predictable over time.

Livzon Pharmaceutical Group News

1513 FAQ

What was Livzon Pharmaceutical Group’s price range in the past 12 months?
Livzon Pharmaceutical Group lowest stock price was HK$19.80 and its highest was HK$32.94 in the past 12 months.
What is Livzon Pharmaceutical Group’s market cap?
Livzon Pharmaceutical Group’s market cap is HK$29.40B.
When is Livzon Pharmaceutical Group’s upcoming earnings report date?
Livzon Pharmaceutical Group’s next earnings report is estimated for Mar 31, 2027 (not yet confirmed), which is in 134 days.
How were Livzon Pharmaceutical Group’s earnings last quarter?
Livzon Pharmaceutical Group released its earnings results on Oct 23, 2026. The company reported HK$0.47 earnings per share for the quarter, missing the consensus estimate of HK$0.567 by -HK$0.097.
Is Livzon Pharmaceutical Group overvalued?
According to Wall Street analysts Livzon Pharmaceutical Group’s price is currently Undervalued.
Does Livzon Pharmaceutical Group pay dividends?
Livzon Pharmaceutical Group pays an annual dividend of HK$1.447 which represents an annual dividend yield of 6.22%. See more information on Livzon Pharmaceutical Group dividends here
What is Livzon Pharmaceutical Group’s EPS estimate?
Livzon Pharmaceutical Group’s EPS estimate is 0.41.
How many shares outstanding does Livzon Pharmaceutical Group have?
Livzon Pharmaceutical Group has 299,807,130 shares outstanding.
What happened to Livzon Pharmaceutical Group’s price movement after its last earnings report?
Livzon Pharmaceutical Group reported an EPS of HK$0.47 in its last earnings report, missing expectations of HK$0.567. Following the earnings report the stock price went up 1.471%.
Which hedge fund is a major shareholder of Livzon Pharmaceutical Group?
Currently, no hedge funds are holding shares in HK:1513
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology